Figure 6.

Lactucin ameliorates liver damage and hepatic fibrosis in mice with CCl₄-induced liver fibrosis. (A) HE staining and Masson’s trichrome staining (400 × magnification); (B–G) The levels of AST, ALT, AKP, LDH, γ-GT and Hyp were measured by Biochemical kits (n = 10); (H–J) The levels of TNF-α, IL-6 and IL-1β in liver tissue were measured by ELISA (n = 6). The data are presented as the means ± SD in each group. *P < 0.05, **P < 0.01 with the Model Group; ^#P < 0.05, ^##P < 0.01 with the Normal Group; Normal healthy mice, Model mice with liver fibrosis, L-Lactucin Lactucin low-dose treatment group, M-Lactucin Lactucin middle-dose treatment group, H-Lactucin Lactucin high-dose treatment group, AST aspartate transaminase, ALT alanine transaminase, AKP alkaline phosphatase, LDH lactate dehydrogenase, γ-GT γ-glutamyl transpeptidase, Hyp hydroxyproline.